Print
18 October 2017
GMP News
An agreement on cooperation between the Association of Kaluga Pharmaceutical Cluster and Steinbeis Global Institute Tübingen at the Steinbeis University Berlin was signed on October 16 by Irina Novikova, the Executive Director of the Association, and Prof. Dr. Bertram Lohmüller, Director of the Institute.
The agreement provides for the implementation of a number of joint training and professional development programs for participants of Kaluga Pharmaceutical Cluster, including such programs as Global Technology Management (Master’s program), Manufacturing and Entry into Global Markets (MBA), Technology Transfer and Business Development MBA), and a number of programs in the area of health care and pharmaceutical manufacturing. According to the mutual arrangement, Steinbeis Global Institute will provide consulting and organizational support to small and medium-sized companies participating in the cluster in their search for partners in Germany and in bringing their products to the European market. For its part, Kaluga Pharmaceutical Cluster will become a “point of entry” to the Russian market for German companies in the area of pharmaceuticals. The agreement also provides for sharing the results of research conducted by the parties, scientific and methodological materials and educational programs.
This agreement was signed during the practical training program for executives from the companies participating in Kaluga Pharmaceutical Cluster in Baden-Württemberg with the active support of the Baden-Württemberg Export Academy.
The RMI group has completed sertain projects
The RMI Group has exited from the capital of portfolio companies:
Marinus Pharmaceuticals, Inc.,
Syndax Pharmaceuticals, Inc.,
Atea Pharmaceuticals, Inc.